NOX-2 Inhibitors may be Potential Drug Candidates for the Management of COVID-19 Complications.

Publication date: Jul 06, 2023

COVID-19 is an RNA virus that attacks the targeting organs, which express angiotensin-converting enzyme-2 (ACE-2), such as the lungs, heart, renal system, and gastrointestinal tract. The virus that enters the cell by endocytosis triggers ROS production within the confines of endosomes via a NOX-2 containing NADPH-oxidase. Various isoforms of NADPH oxidase are expressed in airways and alveolar epithelial cells, endothelial and vascular smooth muscle cells, and inflammatory cells, such as alveolar macrophages, monocytes, neutrophils, and T-lymphocytes. The key NOX isoform expressed in macrophages and neutrophils is the NOX-2 oxidase, whereas, in airways and alveolar epithelial cells, it appears to be NOX-1 and NOX-2. The respiratory RNA viruses induce NOX-2-mediated ROS production in the endosomes of alveolar macrophages. The mitochondrial and NADPH oxidase (NOX) generated ROS can enhance TGF-β signaling to promote fibrosis of the lungs. The endothelium-derived ROS and platelet-derived ROS, due to activation of the NADPH-oxidase enzyme, play a crucial role in platelet activation. It has been observed that NOX-2 is generally activated in COVID-19 patients. The post-COVID complications like pulmonary fibrosis and platelet aggregation may be due to the activation of NOX-2. NOX-2 inhibitors may be a useful drug candidate to prevent COVID-19 complications like pulmonary fibrosis and platelet aggregation.

Concepts Keywords
Ace NADPH-oxidase
Inflammatory NOX-2
Lymphocytes Platelet aggregation
Renal Pulmonary fibrosis
Viruses RNA virus


Type Source Name
disease MESH COVID-19
disease MESH Complications
drug DRUGBANK Angiotensin II
disease IDO cell
pathway KEGG Endocytosis
disease IDO production
disease VO Viruses
disease MESH fibrosis
pathway KEGG Platelet activation
disease MESH pulmonary fibrosis

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *